NS Pharma scores breakthrough therapy status for DMD therapy

NS Pharma’s candidate would be the first to target Duchenne Muscular Dystrophy (DMD) patients amenable to exon 44 skipping therapy.

Jul 29, 2023 - 20:00
NS Pharma scores breakthrough therapy status for DMD therapy
NS Pharma’s candidate would be the first to target Duchenne Muscular Dystrophy (DMD) patients amenable to exon 44 skipping therapy.

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow